Cargando…

Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary

The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due i...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A, Haraoui, Boulos, Kumar, Deepali, Marshall, John K, Bissonnette, Robert, Bitton, Alain, Bressler, Brian, Gooderham, Melinda, Ho, Vincent, Jamal, Shahin, Pope, Janet E, Steinhart, A Hillary, Vinh, Donald C, Wade, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785689/
https://www.ncbi.nlm.nih.gov/pubmed/31616855
http://dx.doi.org/10.1093/jcag/gwy069
_version_ 1783457942167617536
author Papp, Kim A
Haraoui, Boulos
Kumar, Deepali
Marshall, John K
Bissonnette, Robert
Bitton, Alain
Bressler, Brian
Gooderham, Melinda
Ho, Vincent
Jamal, Shahin
Pope, Janet E
Steinhart, A Hillary
Vinh, Donald C
Wade, John
author_facet Papp, Kim A
Haraoui, Boulos
Kumar, Deepali
Marshall, John K
Bissonnette, Robert
Bitton, Alain
Bressler, Brian
Gooderham, Melinda
Ho, Vincent
Jamal, Shahin
Pope, Janet E
Steinhart, A Hillary
Vinh, Donald C
Wade, John
author_sort Papp, Kim A
collection PubMed
description The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive agents.
format Online
Article
Text
id pubmed-6785689
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-67856892019-10-15 Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary Papp, Kim A Haraoui, Boulos Kumar, Deepali Marshall, John K Bissonnette, Robert Bitton, Alain Bressler, Brian Gooderham, Melinda Ho, Vincent Jamal, Shahin Pope, Janet E Steinhart, A Hillary Vinh, Donald C Wade, John J Can Assoc Gastroenterol Original Articles The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive agents. Oxford University Press 2019-12 2019-02-01 /pmc/articles/PMC6785689/ /pubmed/31616855 http://dx.doi.org/10.1093/jcag/gwy069 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Papp, Kim A
Haraoui, Boulos
Kumar, Deepali
Marshall, John K
Bissonnette, Robert
Bitton, Alain
Bressler, Brian
Gooderham, Melinda
Ho, Vincent
Jamal, Shahin
Pope, Janet E
Steinhart, A Hillary
Vinh, Donald C
Wade, John
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
title Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
title_full Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
title_fullStr Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
title_full_unstemmed Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
title_short Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
title_sort vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies—executive summary
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785689/
https://www.ncbi.nlm.nih.gov/pubmed/31616855
http://dx.doi.org/10.1093/jcag/gwy069
work_keys_str_mv AT pappkima vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT haraouiboulos vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT kumardeepali vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT marshalljohnk vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT bissonnetterobert vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT bittonalain vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT bresslerbrian vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT gooderhammelinda vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT hovincent vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT jamalshahin vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT popejanete vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT steinhartahillary vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT vinhdonaldc vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary
AT wadejohn vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary